Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1
Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Inclusion Criteria:
Have confirmed T1D by physician diagnosis
Have normal values at screening for CBC and complete metabolic profiles (with the exception of fasting glucose and HbA1c).
Are able to swallow a capsule.
Are willing to complete weekly online questionnaires.*
Are willing to consume a probiotic or placebo capsule daily for 24 weeks.
Are willing to provide stool samples throughout the study.
Are willing to provide blood samples throughout the study.
Are willing to take three 2-hour Mixed-Meal Tolerance Tests (MMTTs).
Are able to access a computer with Internet throughout the study.*
Exclusion Criteria: